Liberty BioSecurity's Novel Biology Program
Extremophile: (from the Latin extremus meaning "extreme” and the Greek philiā (φιλία) meaning “love”) is an organism that thrives in physically or geochemically extreme conditions that are detrimental to most life on Earth
From discovery to application, Liberty specializes in using cutting edge advances in molecular biology to create new drugs and engineering capabilities from novel extremophile species. Liberty’s unique collection spans species that have mutated on space-based orbiting platforms, to entirely new species isolated thousands of meters deep underground.
Liberty’s scientists leverages this dynamic catalogue of novel species to invent new ways to counter antibiotic resistance, destroy clinical biofilms that enable infection in wounds, counter threats posed by naturally occurring and man-made infectious agents, prevent UV radiation damage, and produce entirely new classes of biological-based materials that can be used by industry.
Extremophile: (from the Latin extremus meaning "extreme” and the Greek philiā (φιλία) meaning “love”) is an organism that thrives in physically or geochemically extreme conditions that are detrimental to most life on Earth
From discovery to application, Liberty specializes in using cutting edge advances in molecular biology to create new drugs and engineering capabilities from novel extremophile species. Liberty’s unique collection spans species that have mutated on space-based orbiting platforms, to entirely new species isolated thousands of meters deep underground.
Liberty’s scientists leverages this dynamic catalogue of novel species to invent new ways to counter antibiotic resistance, destroy clinical biofilms that enable infection in wounds, counter threats posed by naturally occurring and man-made infectious agents, prevent UV radiation damage, and produce entirely new classes of biological-based materials that can be used by industry.
LX-113
Liberty’s lead proprietary drug compound, Lx-113, formerly recognized as Advanced Decontamination and Bioneutralization Material (ADBM), is secreted from a novel organism and is highly effective at destroying biofilms that protect pathogens in human wounds. A drug to mitigate the global health threat posed by biofilms, remains a critical unmet need. LX-113 addresses this need.
LX-113 has been extensively tested by third parties and governments and is projected to enter human trial in 2020.
Thermostable, effective at high temperatures, nontoxic, non-corrosive, and a non-promoter of antibiotic resistance, LX-113 will be used alongside standard of care practices to destroy biofilms that are associated with 80% of all chronic infections in people.[1]
LX-113 has been extensively tested by third parties and governments and is projected to enter human trial in 2020.
Thermostable, effective at high temperatures, nontoxic, non-corrosive, and a non-promoter of antibiotic resistance, LX-113 will be used alongside standard of care practices to destroy biofilms that are associated with 80% of all chronic infections in people.[1]
Development Pipeline
